Inhibition of Glucose-Induced Glycation of HSA by Pioglitazone: Multi-Spectroscopic and Bioinformatic Evidence
Molecules · 03.05.2026 · 31 (9) · 1519
DOI: 10.3390/molecules31091519 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 03.05.2026. Verfasst von Jihad Alrehaili und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 4233-13317, Saudi Arabia. Hauptthemen laut MEDLINE: Pioglitazone, Glucose, Serum Albumin, Human. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research, Imam Mohammad Ibn Saud Islamic University (IMSIU, Imam Mohammad Ibn Saud Islamic University.
Abstract (Originalsprache)
Diabetes mellitus is a growing health concern that causes numerous complications. Glycation produces advanced glycation end-products (AGEs), which promote diabetic complications. Targeting glycation is a strategy for combating the progression of diabetic complications. Pioglitazone enhances insulin sensitivity in patients with type 2 diabetes mellitus, but its impact on glycation remains unclear. This study aims to evaluate whether pioglitazone can inhibit glucose-induced glycation of human serum albumin (HSA), using in vitro assays and in silico tools. Pioglitazone inhibited >70% of early glycation products and >75% of AGEs. The treatment also reduced free lysine modification and improved biochemical markers, including carbonyl and free thiol levels. Pioglitazone exhibited moderate binding affinity for HSA, with a binding constant of 104 M−1. The interaction between pioglitazone and HSA was both spontaneous and entropically favourable. Molecular dynamics simulations revealed that the HSA–pioglitazone complex remained quite stable, with RMSF, RMSD, SASA, Rg, and HSA’s secondary structure showing minimal changes throughout the simulation. The overall binding energy for HSA–pioglitazone complex formation was −30.06 ± 0.31 kcal mol−1, as obtained from MD simulations. The findings suggest that pioglitazone likely interacts with glycation-prone regions of HSA, as indicated by spectroscopic and docking analyses, and contributes to the reduction of glycation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 4233-13317, Saudi Arabia.
ORCID-Profile: Jihad Alrehaili, Razique Anwer
Förderung
- Deanship of Scientific Research, Imam Mohammad Ibn Saud Islamic University (IMSIU
- Imam Mohammad Ibn Saud Islamic University
Zitieren
APA
Alrehaili, J., & Anwer, R. (2026). Inhibition of Glucose-Induced Glycation of HSA by Pioglitazone: Multi-Spectroscopic and Bioinformatic Evidence. Molecules, 31(9), 1519. https://doi.org/10.3390/molecules31091519
Vancouver
Alrehaili J, Anwer R. Inhibition of Glucose-Induced Glycation of HSA by Pioglitazone: Multi-Spectroscopic and Bioinformatic Evidence. Molecules. 2026;31(9):1519. doi:10.3390/molecules31091519
BibTeX
@article{Alrehaili2026,
author = {Alrehaili, Jihad and Anwer, Razique},
title = {Inhibition of Glucose-Induced Glycation of HSA by Pioglitazone: Multi-Spectroscopic and Bioinformatic Evidence},
journal = {Molecules},
year = {2026},
volume = {31},
number = {9},
pages = {1519},
doi = {10.3390/molecules31091519}
}
EUVIMED